Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications
- PMID: 33593397
- PMCID: PMC7884970
- DOI: 10.1186/s13020-021-00433-2
Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications
Abstract
Background: The National Medical Products Administration (NMPA) in China has set to advance the regulatory capacity of traditional Chinese medicines (TCMs) with the adoption of regulatory science (RS). However, the priority of actions at the interface of RS and TCMs were yet to be defined. This research aims to identify the priority areas and summarize core actions for advancing RS for traditional medicines in China.
Methods: A mixed approach of documentary analysis of government policies, regulations and official information about TCMs regulation in China, and a scoping review of literature using 4 databases (PubMed, ScienceDirect, Scopus and CNKI) on major concerns in TCMs regulation was employed.
Results: Ten priority areas in the development of TCM-related regulatory science in China have been identified, including: (1) modernizing the regulatory system with a holistic approach; (2) advancing the methodology for the quality control of TCMs; (3) fostering the control mechanism of TCMs manufacturing process; (4) improving clinical evaluation of TCMs and leveraging real world data; (5) re-evaluation of TCMs injection; (6) developing evaluation standards for classic TCMs formula; (7) harnessing diverse data to improve pharmacovigilance of TCMs; (8) evaluating the value of integrative medicine in clinical practice with scientific research; (9) advancing the regulatory capacity to encourage innovation in TCMs; and (10) advancing a vision of collaboration for RS development in TCMs.
Conclusions: RS for TCMs in China encompasses revolution of operational procedures, advancement in science and technology, and cross-disciplinary collaborations. Such experiences could be integrated in the communications among drug regulatory authorities to promote standardized and scientific regulation of traditional medicines.
Keywords: China; Drug Regulatory Authority; National Medical Products Administration; Regulatory Science; TCM; Traditional medicine.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Gispen-de Wied CC, Leufkens HGM. From molecule to market access: drug regulatory science as an upcoming discipline. Eur J Pharmacol. 2013;719(1–3):9–15. - PubMed
-
- US Food and Drug Administration. Advancing regulatory science at FDA: a strategic plan. 2011. https://www.fda.gov/media/81109/download. Accessed 30 Jun 2020.
-
- European Medicines Agency. Regulatory Science Strategy to 2025. 2019. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/e.... Accessed 30 Jun 2020.
-
- Japanese Pharmaceuticals and Medical Devices Agency. Outline of regulatory science. https://www.pmda.go.jp/english/rs-sb-std/rs/0003.html. Accessed 30 Jun 2020.
-
- The Center People’s Government of the PRC. NMPA has initiated the “Action Plan on Regulatory Science in China. http://www.gov.cn/xinwen/2019-05/02/content_5388253.htm. Accessed 30 Jun 2020 (Chinese).
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources